Excess in the pharmaceutical industry

被引：76

作者：

Angell, M ^{[1
]}

机构：

[1] Harvard Univ, Sch Med, Cambridge, MA 02138 USA

来源：

关键词：

D O I：

10.1503/cmaj.1041594

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1451 / 1453

页数：3

共 12 条

[1] AARON C, 2003, OTHER DRUG WAR 2003
[2] BOUTON D, 2003, PUBL FAMILIES US, V3106
[3] Harris G, 2002, WALL STREET J A 0418, P1
[4] HENSLEY S, 2003, WALL STREET J D 0415, P4
[5] *HJ KAIS FAM FDN, 2001, PUBL HJ KAIS FAM FDN, V3112, P45
[6] Trends - Health spending rebound continues in 2002
Levit, K
Smith, C
Cowan, C
Sensenig, A
Catlin, A
[J]. HEALTH AFFAIRS, 2004, 23 (01) : 147 - 159
[7] MAHAN D, 2002, PUBL FAMILIES US, V2105
[8] PATTISON N, 2003, 2002 DRUG IND PROFIT
[9] *PHRMA, 2002, PHARM IND PROF 2002, P79
[10] Separating continuing medical education from pharmaceutical marketing
Relman, AS
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (15): : 2009 - 2012